Literature DB >> 12351997

Muscular dystrophies.

Ichizo Nishino1, Eijiro Ozawa.   

Abstract

PURPOSE OF REVIEW: Muscular dystrophy includes many genetically distinct disorders. The list of causative genes for muscular dystrophy has been expanding rapidly, including those for congenital muscular dystrophies. RECENT
FINDINGS: We review the newly identified causative genes and suggested molecular mechanisms, focusing on glycosylation abnormality of alpha-dystroglycan, collagen VI deficiency, four allelic diseases of caveolin-3 gene, and titin gene mutations.
SUMMARY: Several possible mechanisms causing muscular dystrophy were discussed. Defects in extracellular molecules have more significant effects resulting mainly in congenital muscular dystrophy, while intracellular molecular defects show milder effect on the phenotype. These hypotheses may provide a new paradigm in understanding the pathomechanism of muscular dystrophies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12351997     DOI: 10.1097/00019052-200210000-00004

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  8 in total

Review 1.  M-band: a safeguard for sarcomere stability?

Authors:  Irina Agarkova; Elisabeth Ehler; Stephan Lange; Roman Schoenauer; Jean-Claude Perriard
Journal:  J Muscle Res Cell Motil       Date:  2003       Impact factor: 2.698

2.  Mdm muscular dystrophy: interactions with calpain 3 and a novel functional role for titin's N2A domain.

Authors:  Kimberly A Huebsch; Elena Kudryashova; Christine M Wooley; Roger B Sher; Kevin L Seburn; Melissa J Spencer; Gregory A Cox
Journal:  Hum Mol Genet       Date:  2005-08-22       Impact factor: 6.150

3.  Crossveinless and the TGFbeta pathway regulate fiber number in the Drosophila adult jump muscle.

Authors:  Maryann S Jaramillo; Candice V Lovato; Erica M Baca; Richard M Cripps
Journal:  Development       Date:  2009-02-25       Impact factor: 6.868

4.  Improved regenerative myogenesis and muscular dystrophy in mice lacking Mkp5.

Authors:  Hao Shi; Mayank Verma; Lei Zhang; Chen Dong; Richard A Flavell; Anton M Bennett
Journal:  J Clin Invest       Date:  2013-04-01       Impact factor: 14.808

Review 5.  Therapeutics for Duchenne muscular dystrophy: current approaches and future directions.

Authors:  Sasha Bogdanovich; Kelly J Perkins; Thomas O B Krag; Tejvir S Khurana
Journal:  J Mol Med (Berl)       Date:  2003-12-12       Impact factor: 4.599

6.  Gene expression profiling of Duchenne muscular dystrophy skeletal muscle.

Authors:  Judith N Haslett; Despina Sanoudou; Alvin T Kho; Mei Han; Richard R Bennett; Isaac S Kohane; Alan H Beggs; Louis M Kunkel
Journal:  Neurogenetics       Date:  2003-04-16       Impact factor: 2.660

7.  Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of muscular dystrophy model mice.

Authors:  K Tsuchida
Journal:  Acta Myol       Date:  2008-07

Review 8.  Protein Quality Control at the Sarcomere: Titin Protection and Turnover and Implications for Disease Development.

Authors:  Sebastian Kötter; Martina Krüger
Journal:  Front Physiol       Date:  2022-06-30       Impact factor: 4.755

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.